IRIS Accounts Production v26.1.0.640 05948662 director 1.10.24 30.9.25 30.9.25 false true false false false true false Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 05948662 2024-09-30 05948662 2025-09-30 05948662 2024-10-01 2025-09-30 05948662 2023-09-30 05948662 2023-10-01 2024-09-30 05948662 2024-09-30 05948662 ns15:EnglandWales 2024-10-01 2025-09-30 05948662 ns14:PoundSterling 2024-10-01 2025-09-30 05948662 ns10:Director1 2024-10-01 2025-09-30 05948662 ns10:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 05948662 ns10:SmallEntities 2024-10-01 2025-09-30 05948662 ns10:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 05948662 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-01 2025-09-30 05948662 ns10:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 05948662 ns10:FullAccounts 2024-10-01 2025-09-30 05948662 1 2024-10-01 2025-09-30 05948662 ns10:OrdinaryShareClass1 2024-10-01 2025-09-30 05948662 ns10:CompanySecretary1 2024-10-01 2025-09-30 05948662 ns10:RegisteredOffice 2024-10-01 2025-09-30 05948662 ns5:CurrentFinancialInstruments 2025-09-30 05948662 ns5:CurrentFinancialInstruments 2024-09-30 05948662 ns5:Non-currentFinancialInstruments 2025-09-30 05948662 ns5:Non-currentFinancialInstruments 2024-09-30 05948662 ns5:ShareCapital 2025-09-30 05948662 ns5:ShareCapital 2024-09-30 05948662 ns5:RetainedEarningsAccumulatedLosses 2025-09-30 05948662 ns5:RetainedEarningsAccumulatedLosses 2024-09-30 05948662 ns5:NetGoodwill 2024-10-01 2025-09-30 05948662 ns5:IntangibleAssetsOtherThanGoodwill 2024-10-01 2025-09-30 05948662 ns5:FurnitureFittings 2024-10-01 2025-09-30 05948662 ns5:NetGoodwill 2024-09-30 05948662 ns5:NetGoodwill 2025-09-30 05948662 ns5:NetGoodwill 2024-09-30 05948662 ns5:FurnitureFittings 2024-09-30 05948662 ns5:FurnitureFittings 2025-09-30 05948662 ns5:FurnitureFittings 2024-09-30 05948662 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-09-30 05948662 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-09-30 05948662 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2025-09-30 05948662 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2024-09-30 05948662 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2025-09-30 05948662 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2024-09-30 05948662 ns5:BetweenOneFiveYears 2025-09-30 05948662 ns5:BetweenOneFiveYears 2024-09-30 05948662 ns5:MoreThanFiveYears 2025-09-30 05948662 ns5:MoreThanFiveYears 2024-09-30 05948662 ns5:AllPeriods 2025-09-30 05948662 ns5:AllPeriods 2024-09-30 05948662 ns5:Secured 2025-09-30 05948662 ns5:Secured 2024-09-30 05948662 ns5:DeferredTaxation 2024-09-30 05948662 ns5:DeferredTaxation 2025-09-30 05948662 ns10:OrdinaryShareClass1 2025-09-30 05948662 ns5:RetainedEarningsAccumulatedLosses 2024-09-30 05948662 ns5:RetainedEarningsAccumulatedLosses 2024-10-01 2025-09-30

REGISTERED NUMBER: 05948662 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025

FOR

RADCLIFFE PHARMACY LIMITED

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

RADCLIFFE PHARMACY LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 30 SEPTEMBER 2025

| DIRECTOR: | Mr S Iqbal

| SECRETARY: | Mrs A Iqbal

| REGISTERED OFFICE: | 2 Cedargrove

| Hagley

| Stourbridge

| West Midlands

| DY9 0DR

| REGISTERED NUMBER: | 05948662 (England and Wales)

| ACCOUNTANTS: | Ashcrofts Accountants Limited

| 2 Cedargrove

| Hagley

| Stourbridge

| West Midlands

| DY9 0DR

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

BALANCE SHEET

30 SEPTEMBER 2025

| 2025 |  | 2024

| Notes | £ | £ |

FIXED ASSETS

Intangible assets | 4 | 304,792 |  | 322,292 |  |

Tangible assets | 5 | 30,908 |  | 37,170 |  |

335,700 |  | 359,462 |  |

CURRENT ASSETS

Stocks | 6 | 100,670 |  | 94,705 |  |

Debtors | 7 | 580,897 |  | 938,650 |  |

Cash at bank and in hand | 172,444 |  | 268,774 |  |

854,011 |  | 1,302,129 |  |

CREDITORS

Amounts falling due within one year | 8 | (345,866 | ) | (727,743 | ) |

NET CURRENT ASSETS | 508,145 |  | 574,386 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 843,845 |  | 933,848 |  |

CREDITORS

Amounts falling due after more than one year | 9 | (314,659 | ) | (342,641 | ) |

PROVISIONS FOR LIABILITIES | 13 | (1,608 | ) | (866 | ) |

NET ASSETS | 527,578 |  | 590,341 |  |

CAPITAL AND RESERVES

Called up share capital | 14 | 100 |  | 100 |  |

Retained earnings | 15 | 527,478 |  | 590,241 |  |

SHAREHOLDERS' FUNDS | 527,578 |  | 590,341 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

BALANCE SHEET - continued

30 SEPTEMBER 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 5 April 2026 and were signed by:

Mr S Iqbal - Director

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2025

1. | STATUTORY INFORMATION

| Radcliffe Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Goodwill

| Goodwill, being the amount paid in connection with the acquisition of a business in 2023, is being amortised evenly over its estimated useful life of twenty years.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

| Fixtures, fittings & equipment | - | 25% on reducing balance

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

2. | ACCOUNTING POLICIES - continued

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 23 (2024 - 27 ) .

4. | INTANGIBLE FIXED ASSETS

| Goodwill

£ |

| COST

| At 1 October 2024

| and 30 September 2025 | 350,000 |  |

| AMORTISATION

| At 1 October 2024 | 27,708 |  |

| Amortisation for year | 17,500 |  |

| At 30 September 2025 | 45,208 |  |

| NET BOOK VALUE

| At 30 September 2025 | 304,792 |  |

| At 30 September 2024 | 322,292 |  |

5. | TANGIBLE FIXED ASSETS

| Fixtures,

| fittings

| & equipment

£ |

| COST

| At 1 October 2024 | 192,274 |  |

| Additions | 3,815 |  |

| At 30 September 2025 | 196,089 |  |

| DEPRECIATION

| At 1 October 2024 | 155,104 |  |

| Charge for year | 10,077 |  |

| At 30 September 2025 | 165,181 |  |

| NET BOOK VALUE

| At 30 September 2025 | 30,908 |  |

| At 30 September 2024 | 37,170 |  |

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

6. | STOCKS

2025 | 2024 |

£ | £ |

| Stocks | 100,670 |  | 94,705 |  |

7. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 213,813 |  | 249,218 |  |

| Other debtors | 307,192 |  | 660,192 |  |

| VAT | 54,447 |  | 24,346 |  |

| Prepayments and accrued income | 5,445 |  | 4,894 |  |

580,897 |  | 938,650 |  |

8. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans and overdrafts (see note 10) | 21,764 |  | 23,829 |  |

| Trade creditors | 313,651 |  | 311,052 |  |

| Social security and other taxes | 5,139 |  | 3,769 |  |

| Other creditors | 907 |  | 100,905 |  |

| Directors' loan accounts | 1,174 |  | 285,007 |  |

| Accruals and deferred income | 3,231 |  | 3,181 |  |

345,866 |  | 727,743 |  |

9. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans (see note 10) | 314,659 |  | 342,641 |  |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 248,270 |  | 272,258 |  |

10. | LOANS

| An analysis of the maturity of loans is given below:

2025 | 2024 |

£ | £ |

| Amounts falling due within one year or on demand:

| Bank loans | 21,764 |  | 23,829 |  |

| Amounts falling due between one and two years:

| Bank loans - 1-2 years | 15,697 |  | 25,029 |  |

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

10. | LOANS - continued

2025 | 2024 |

£ | £ |

| Amounts falling due between two and five years:

| Bank loans - 2-5 years | 50,692 |  | 45,354 |  |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 248,270 |  | 272,258 |  |

11. | LEASING AGREEMENTS

| Minimum lease payments under non-cancellable operating leases fall due as follows:

2025 | 2024 |

£ | £ |

| Between one and five years | 2,520 |  | 2,873 |  |

| In more than five years | 20,000 |  | 27,200 |  |

22,520 |  | 30,073 |  |

12. | SECURED DEBTS

| The following secured debts are included within creditors:

2025 | 2024 |

£ | £ |

| Bank loans | 336,423 |  | 366,470 |  |

13. | PROVISIONS FOR LIABILITIES

2025 | 2024 |

£ | £ |

| Deferred tax | 1,608 |  | 866 |  |

| Deferred |

| tax |

£ |

| Balance at 1 October 2024 | 866 |  |

| Charged during the year | 742 |  |

| Balance at 30 September 2025 | 1,608 |  |

14. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary | £1 | 100 |  | 100 |  |

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

15. | RESERVES

| Retained

| earnings

£ |

| At 1 October 2024 | 590,241 |  |

| Deficit for the year | (14,763 | ) |

| Dividends | (48,000 | ) |

| At 30 September 2025 | 527,478 |  |

16. | DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

| At 30 September 2025 there was a loan from Mr S Iqbal of £1,174 (2024: £285,007). This unsecured loan is interest free and repayable on demand.